An update on metabolism studies using human hepatocytes in primary culture

Bibliography

• Soars MG, Mcginnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 2007;168:2-15
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Donato T, Ponsoda X, Castell JV. Human hepatic cell cultures: in vitro and in vivo drug metabolism. Altern Lab Anim 2003;31:257-65
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metab 2004;5:443-62
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Castell JV, Donato MT. Hepatocytes – the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 2007;168:30-50
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Gomez-Lechón MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes, transporter proteins and how they are used in pharmaceutical practice. Drug Metab Rev 2007;39:159-234
   PubMed Web of Science ®Google Scholar
• Ortiz De Montellano PR, De Voss JJ. Oxidizing species in the mechanism of cytochrome P450. Nat Prod Rep 2002;19:477-93
   PubMed Web of Science ®Google Scholar
• Cytochrome P450 home page. Available from: http://drnelson.utmem.edu/CytochromeP450.html
   Google Scholar
• Nedelchava V, Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994;24:1151-75
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23
   PubMed Web of Science ®Google Scholar
• Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 2003;42:153-78
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ. Fluorescence-based assays for screening nine CYP activities in intact cells expressing individual human CYP enzymes. Drug Metab Disp 2004;32:699-706
   PubMed Web of Science ®Google Scholar
• Lahoz A, Donato MT, Castell JV, Gómez-Lechón MJ. Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry. Curr Drug Metab 2008;9:12-9
   PubMed Web of Science ®Google Scholar
• Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007;28:257-62
   PubMed Web of Science ®Google Scholar
• Lahoz A, Donato MT, Picazo L, et al. Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. Toxicol In Vitro 2007;21:1247-52
   PubMed Web of Science ®Google Scholar
• Tolonen A, Petsalo A, Turpeinen M, et al. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007;42:960-6
   PubMed Web of Science ®Google Scholar
• Testino SA Jr, Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003;30:1459-67
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Li SQ, Carter GT. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm 2007;335:1-11
   PubMedGoogle Scholar
• Burczynski ME, Mcmillian M, Parker JB, et al. Cytochrome P450 induction in rat hepatocytes assessed by quantitative real-time reverse-transcription polymerase chain reaction and the RNA invasive cleavage assay. Drug Metab Dispos 2001;29:1243-50
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Donato MT, Gómez-Lechón MJ, Castell JV. CYP mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001;393:308-15
   PubMed Web of Science ®Google Scholar
• Pérez G, Tabares B, Jover R, et al. Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol In Vitro 2003;17:643-9
   PubMed Web of Science ®Google Scholar
• Sumida A, Kinoshita K, Fukuda T, et al. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver. Biochem Biophys Res Commun 1999;262:499-503
   PubMed Web of Science ®Google Scholar
• Ning B, Dial S, Sun Y, et al. Systematic and simultaneous gene profiling of 84 drug-metabolizing genes in primary human hepatocytes. J Biomol Screen 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Rodríguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32:505-20
   PubMed Web of Science ®Google Scholar
• Woodcroft KJ, Novak RF. Xenobiotic-enhanced expression of cytochromes P450 2E1 and 2B in primary cultured rat hepatocytes. Drug Metab Dispos 1998;26:372-8
   PubMed Web of Science ®Google Scholar
• Lecluyse EL. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharmac Sci 2001;13:343-68
   PubMed Web of Science ®Google Scholar
• Maurel P. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Deliv Rev 1996;22:105-32
   Web of Science ®Google Scholar
• Li AP, Maurel P, Gomez-Lechon MJ, et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 1997;107:5-16
   PubMed Web of Science ®Google Scholar
• Li AP. The hepatocyte review. In: Berry MN, Edwards AM, editors, Human hapatocytes as an experimental system for the evaluation of xenobiotics. Kluwer Academic Publishers: Netherlands; 2000. p. 391-410
   Google Scholar
• Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168:16-29
   PubMed Web of Science ®Google Scholar
• Elaut G, Henkens T, Papeleu P, et al. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 2006;7:629-60
   PubMed Web of Science ®Google Scholar
• Pascussi JM, GerbaL-Chaloin S, Fabre JM, et al. Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 2000;58:1441-50
   PubMed Web of Science ®Google Scholar
• Runge D, Runge DM, Jäger D, et al. Serum-free, long-term cultures of human hepatocytes: maintenance of cell morphology, transcription factors, and liver-specific functions. Biochem Biophys Res Commun 2000;269:46-53
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Liu F, Omiecinski CJ. Phenobarbital responsiveness as a uniquely sensitive indicator of hepatocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp Cell Res 2004;292:252-64
   PubMed Web of Science ®Google Scholar
• Turncliff RZ, Meier PJ, Brouwer KL. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab Dispos 2004;32:834-49
   PubMed Web of Science ®Google Scholar
• Dunn JC, Yarmush ML, Koebe HG, Tompkins RG. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J 1989;3:174-7
   PubMed Web of Science ®Google Scholar
• Dunn JC, Tompkins RG, Yarmush ML. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 1991;7:237-45
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Jover R, Donato T, et al. Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J Cell Physiol 1998;177:553-62
   PubMed Web of Science ®Google Scholar
• Richert L, Binda D, Hamilton G, et al. Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capacities of cultured rat hepatocytes. Toxicol In Vitro 2002;16:89-99
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Donato T, Ponsoda X, et al. In vitro methods in Pharm. Res. In: Castell JV, Gómez-Lechón MJ, editors, Isolation, culture ad use of human hepatocytes in drug research. Academic Press: London; 1997. p. 129-53
   Google Scholar
• Chen HL, Wu HL, Fon CC, et al. Long-term culture of hepatocytes from human adults. J Biomed Sci 1998a;5:435-40
   PubMed Web of Science ®Google Scholar
• Hino H, Tateno C, Sato H, et al. A long-term culture of human hepatocytes which show a high growth potential and express their differentiated phenotypes. Biochem Biophys Res Commun 1999;256:184-91
   PubMed Web of Science ®Google Scholar
• Guguen-Guillouzo C, Clement B, Baffet G, et al. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp Cell Res 1983;143:47-54
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Re-expression of C/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 1998;431:227-30
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001;33:668-75
   PubMed Web of Science ®Google Scholar
• Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 2002;16:1799-801
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007;8:185-94
   PubMed Web of Science ®Google Scholar
• Rialland L, Guyomard C, Scotte M. Viability and drug metabolism capacity of alginate-entrapped hepatocytes after cryopreservation. Cell Biol Toxicol 2000;16:105-16
   PubMed Web of Science ®Google Scholar
• Miller MS, Mccarver DG, Bell DA, et al. Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol 1997;40:1-14
   PubMedGoogle Scholar
• Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol Appl Pharmacol 2005;207:S52-6
   PubMedGoogle Scholar
• Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolise testosterone and chlorpyrifos. J Pharmacol ExpTher 2001;299:825-31
   PubMed Web of Science ®Google Scholar
• Gervasini G, García-Martín E, Ladero JM, et al. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer 2007;7:118
   PubMedGoogle Scholar
• Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007;63:321-33
   PubMed Web of Science ®Google Scholar
• Aueviriyavit S, Furihata T, Morimoto K, et al. Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers. Drug Metab Pharmacokinet 2007;22:391-8
   PubMed Web of Science ®Google Scholar
• Dorne JL. Human variability in hepatic and renal elimination: implications for risk assessment. J Appl Toxicol 2007;27:411-20
   PubMed Web of Science ®Google Scholar
• Ponsoda X, Pareja E, Gómez-Lechón MJ, et al. Drug biotransformation by human hepatocytes: in vitro/in vivo metabolism by cells from the same donor. J Hepatol 2001;34:19-25
   PubMed Web of Science ®Google Scholar
• Bort R, Ponsoda X, Carrasco E, et al. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996;24:834-41
   PubMed Web of Science ®Google Scholar
• Bort R, Ponsoda X, Carrasco E, et al. Comparative metabolism of nonsteroidal antiinflamatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos 1996;24:969-75
   PubMed Web of Science ®Google Scholar
• Mcginnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004;32:1247-53
   PubMed Web of Science ®Google Scholar
• Andersson TB, Sjöberg H, Hoffmann KJ, et al. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 2001;29:712-20
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Myllynen P, Taavitsainen P, et al. Carbamazepine: a ‘blind’ assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001;31:321-43
   PubMed Web of Science ®Google Scholar
• Salonen JS, Nyman L, Boobis AR, et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 2003;31:1093-02
   PubMed Web of Science ®Google Scholar
• Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1984;47:1469-79
   Google Scholar
• Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 2004;32:973-82
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003;31:580-8
   PubMed Web of Science ®Google Scholar
• Miners JO, Knights KM, Houston JB, Mackenzie PI. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 2006;71:1531-9
   PubMed Web of Science ®Google Scholar
• Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharm Exp Ther 2002;301:382-90
   PubMed Web of Science ®Google Scholar
• Liu L, Pang KS. An integrated approach to model hepatic drug clearance. Eur J Pharm Sci 2006;29:215-30
   PubMed Web of Science ®Google Scholar
• Nagilla R, Frank KA, Jolivette LJ, Ward KW. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 2006;53:106-16
   PubMedGoogle Scholar
• Pelkonen O, Turpeinen M. In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 2007;37:1066-89
   PubMed Web of Science ®Google Scholar
• Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007;8:33-45
   PubMed Web of Science ®Google Scholar
• Bachmann KA, Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2001;2:299-314
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Itoga H, Kohno Y, et al. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. Xenobiotica 2005;35:627-46
   PubMed Web of Science ®Google Scholar
• Lau YY, Sapidou E, Cui X, et al. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metab Dispos 2002;30:1446-54
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 2002;30:892-6
   PubMed Web of Science ®Google Scholar
• Blanchard N, Hewitt NJ, Silber P, et al. Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations. J Pharm Pharmacol 2006;58:633-41
   PubMed Web of Science ®Google Scholar
• Eneroth A, Vrang L, Astner L, et al. Clearance studies using cryopreserved pooled human hepatocytes: reproducibility within one lot and between lots. Drug Metab Rev 2006;38:61-2
   Google Scholar
• Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004;21:785-92
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Houston JB. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos 2005;33:115-20
   PubMed Web of Science ®Google Scholar
• Levesque JF, Templeton E, Trimble L, et al. Discovery, biosynthesis, and structure elucidation of metabolites of a doping agent and a direct analogue, tetrahydrogestrinone and gestrinone, using human hepatocytes. Anal Chem 2005;77:3164-72
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang L, Chandrasena G, et al. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos 2007;35:139-49
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Buhring KU, Dasenbrock J, et al. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 2001;29:1042-50
   PubMed Web of Science ®Google Scholar
• Gebhardt R, Hengstler JG, Müller D, et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 2003;35:145-213
   PubMed Web of Science ®Google Scholar
• Suchanova B, Kostiainen R, Ketola RA. Characterization of the in vitro metabolic profile of amlodipine in rat using liquid chromatography-mass spectrometry. Eur J Pharm Sci 2008;33:91-9
   PubMed Web of Science ®Google Scholar
• Gao H, Materne OL, Howe DL, Brummel CL. Method for rapid metabolite profiling of drug candidates in fresh hepatocytes using liquid chromatography coupled with a hybrid quadrupole linear ion trap. Rapid Commun Mass Spectrom 2007;21:3683-93
   PubMed Web of Science ®Google Scholar
• Yang Z. Online hyphenated liquid chromatography-nuclear magnetic resonance spectroscopy-mass spectrometry for drug metabolite and nature product analysis. J Pharm Biomed Anal 2006;40:516-27
   PubMed Web of Science ®Google Scholar
• Brandon EF, Van Ooijen RD, Sparidans RW, et al. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. J Mass Spectrom 2005;40:821-31
   PubMed Web of Science ®Google Scholar
• Shou WZ, Magis L, Li AC, et al. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. J Mass Spectrom 2005;40:1347-56
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90
   PubMed Web of Science ®Google Scholar
• Donato MT, Gómez-Lechón MJ. Inhibition of P450 enzymes: an in vitro approach. Curr Enzyme Inhibition 2006;2:281-4
   Google Scholar
• Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997;248:188-90
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69
   PubMed Web of Science ®Google Scholar
• Di Marco A, Yao D, Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem 2003;270:3768-77
   PubMedGoogle Scholar
• Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos 2005;33:853-61
   PubMed Web of Science ®Google Scholar
• Mcginnity DF, Berry AJ, Kenny JR, et al. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-300
   PubMed Web of Science ®Google Scholar
• Baranczewski P, Edlund PO, Postlind H. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems. J Pharm Biomed Anal 2006;40:1121-30
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70:103-14
   PubMedGoogle Scholar
• Donato MT, Gómez-Lechón MJ, Castell JV. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993;213:29-33
   PubMed Web of Science ®Google Scholar
• Price RJ, Surry D, Renwick AB, et al. CYP isoform induction screening in 96-well plates: use of 7-benzyloxy-4-trifluoromethylcoumarin as a substrate for studies with rat hepatocytes. Xenobiotica 2000;30:781-95
   PubMed Web of Science ®Google Scholar
• Mcginnity DF, Tucker J, Trigg S, Riley RJ. Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 2005;33:1700-77
   PubMed Web of Science ®Google Scholar
• Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans. Biopharm Drug Dispos 2006;27:267-73
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-7
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-8
   PubMed Web of Science ®Google Scholar
• Gebhardt R, Hengstler JG, Müller D, et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 2003;35:145-213
   PubMed Web of Science ®Google Scholar
• Reddy A, Heimbach T, Freiwald S, et al. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J Pharm Biomed Anal 2005;37:319-26
   PubMed Web of Science ®Google Scholar
• Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998;23:403-16
   PubMed Web of Science ®Google Scholar
• Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92
   PubMed Web of Science ®Google Scholar
• Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56:1329-39
   PubMed Web of Science ®Google Scholar
• Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23
   PubMed Web of Science ®Google Scholar
• Lin JH, Wong BK. Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 2002;3:623-46
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, de Kanter R, LeCluyse E. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry – do they comply with FDA recommendations? Chem Biol Interact 2007;168:51-65
   PubMed Web of Science ®Google Scholar
• Guidance for industry: Drug interaction studies – Study design, data analysis, and implications for dosing and labelling. Guidance draft. 2006. Available from: www.fda.gov/cber/gdlns/interactstud.htm
   Google Scholar
• Martin H, Sarsat JP, De Waziers I, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 2003;20:557-68
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31
   PubMed Web of Science ®Google Scholar
• Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 2004;32:348-58
   PubMed Web of Science ®Google Scholar
• Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999;48:168-79
   PubMed Web of Science ®Google Scholar
• Li AP, Hartman NR, Lu C, et al. Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytes. Br J Clin Pharmacol 1999;48:733-42
   PubMed Web of Science ®Google Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-57
   PubMed Web of Science ®Google Scholar
• Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos 2007;35:419-27
   PubMed Web of Science ®Google Scholar
• Ritter JK, Kessler FK, Thompson MT, et al. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology 1999;30:476-84
   PubMed Web of Science ®Google Scholar
• Soars MG, Petullo DM, Eckstein JA, et al. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004;32:140-8
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, et al. Comparative effects of fibrates on drug metabolizing enzymes in human Hepatocytes. Pharm Res 2005;22:71-8
   PubMed Web of Science ®Google Scholar
• Jemnitz K, Veres Z, Vereczkey L. Coordinate regulation of UDP glucuronosyltransferase UGT1A6 induction by 3-methylcholanthrene and multidrug resistance protein MRP2 expression by dexamethasone in primary rat hepatocytes. Biochem Pharmacol 2002;63:2137-44
   PubMed Web of Science ®Google Scholar
• Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006;34:75-83
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7:375-88
   PubMed Web of Science ®Google Scholar
• Puzyn T, Falandysz J, Jones PD, Giesy JP. Quantitative structure-activity relationships for the prediction of relative in vitro potencies (REPs) for chloronaphthalenes. J Environ Sci Health A Tox Hazard Subst Environ Eng 2007;42:573-90
   PubMed Web of Science ®Google Scholar
• Youdim KA, Tyman CA, Jones BC, Hyland R. Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab Dispos 2007;35:275-82
   PubMed Web of Science ®Google Scholar
• Kafert-Kasting S, Alexandrova K, Barthold M, et al. Enzyme induction in cryopreserved human hepatocyte cultures. Toxicology 2006;220:117-25
   PubMed Web of Science ®Google Scholar
• Terry C, Dhawan A, Mitry RR, Hughes RD. Cryopreservation of isolated human hepatocytes for transplantation: state of the art. Cryobiology 2006;53:149-59
   PubMed Web of Science ®Google Scholar
• Terry C, Hughes RD, Mitry RR, et al. Cryopreservation-induced nonattachment of human hepatocytes: role of adhesion molecules. Cell Transplant 2007;16:639-47
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang D, Cui D, et al. Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 2007;35:2270-80
   PubMed Web of Science ®Google Scholar
• Soars MG, Ring BJ, Wrighton SA. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 2003;31:762-7
   PubMed Web of Science ®Google Scholar
• Webborn PJ, Parker AJ, Denton RL, Riley RJ. In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 2007;37:1090-109
   PubMed Web of Science ®Google Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
   PubMed Web of Science ®Google Scholar
• Guillouzo A, Corlu A, Aninat C, et al. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007;168:66-73
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008;36:137-45
   PubMed Web of Science ®Google Scholar
• Castell JV, Jover R, Martínez-Jiménez CP, Gómez-Lechón MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006;2:183-212
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Castell JV, Gómez-LechóN MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008;9:1-11
   PubMed Web of Science ®Google Scholar
• Scheuenpflug J, Krebsfänger N, Doehmer J. Heterologous co-expression of human cytochrome P450 1A2 and polymorphic forms of N-acetyltransferase 2 for studies on aromatic amines in V79 Chinese hamster cells. Altern Lab Anim 2005;33:561-77
   PubMed Web of Science ®Google Scholar
• Goldring CE, Kitteringham NR, Jenkins R, et al. Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes. Am J Physiol Cell Physiol 2006;290:C104-15
   PubMedGoogle Scholar
• Ek M, Söderdahl T, Küppers-Munther B, et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007;74:496-503
   PubMed Web of Science ®Google Scholar
• Hengstler JG, Brulport M, Schormann W, et al. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol 2005;1:61-74
   PubMedGoogle Scholar
• Eberhardt M, Salmon P, Von Mach MA, et al. Multipotential nestin and Isl-1 positive mesenchymal stem cells isolated from human pancreatic islets. Biochem Biophys Res Commun 2006;345:1167-76
   PubMed Web of Science ®Google Scholar
• Nussler A, Konig S, Ott M, et al. Present status and perspectives of cell-based therapies for liver diseases. J Hepatol 2006;45:144-59
   PubMed Web of Science ®Google Scholar
• Taléns-Visconti R, BonorA-Centelles A, Castell JV, Gómez-Lechón MJ. Alternative sources of hepatocytes for cell therapy. Gastroenterol Hepatol 2006;29:366-76
   PubMedGoogle Scholar
• Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26:120-6
   PubMed Web of Science ®Google Scholar
• Dierks EA, Stams KR, Lim HK, et al. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001;29:23-9
   PubMed Web of Science ®Google Scholar
• Weaver R, Graham KS, Beattie IG, Riley RJ. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 2003;31:955-66
   PubMed Web of Science ®Google Scholar
• Bu HZ, Magis L, Knuth K, Teitelbaum P. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Rapid Commun Mass Spectrom 2001;15:741-8
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005;24:123-32
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, et al. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:2651-8
   PubMed Web of Science ®Google Scholar
• Lahoz A, Donato MT, Montero S, et al. In vitro cocktail assay for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations. Rapid Commun Mass Spectrom 2008;22:240-4
   PubMed Web of Science ®Google Scholar